You might be correct about the size of the GBM market in the UK. However you are missing the point.
Approval in the UK validates the MOA and the potential of treating other solid cancers. That will have much more impact than the limited size of the UK market.
Approval in the UK will open up funding sources for NWBO allowing it to move forward at a pace that has heretofore been resource limited. Invertors and BP will recognize that.
Approval in the UK may be a small thing by itself. It is also a paradigm shift which is huge.
Market Data 
Markets 
AI
